131 related articles for article (PubMed ID: 30235492)
21. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.
Salvi M; Pedrazzoni M; Girasole G; Giuliani N; Minelli R; Wall JR; Roti E
Eur J Endocrinol; 2000 Aug; 143(2):197-202. PubMed ID: 10913938
[TBL] [Abstract][Full Text] [Related]
22. DIAGNOSIS OF ENDOCRINE DISEASE: IgG4-related thyroid autoimmune disease.
Rotondi M; Carbone A; Coperchini F; Fonte R; Chiovato L
Eur J Endocrinol; 2019 May; 180(5):R175-R183. PubMed ID: 30889549
[TBL] [Abstract][Full Text] [Related]
23. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.
Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y
Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111
[TBL] [Abstract][Full Text] [Related]
24. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
25. Distribution of serum immunoglobulin G4 levels in Hashimoto's thyroiditis and clinical features of Hashimoto's thyroiditis with elevated serum immunoglobulin G4 levels.
Takeshima K; Ariyasu H; Inaba H; Inagaki Y; Yamaoka H; Furukawa Y; Doi A; Furuta H; Nishi M; Akamizu T
Endocr J; 2015; 62(8):711-7. PubMed ID: 25994040
[TBL] [Abstract][Full Text] [Related]
26. Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease.
Mizuguchi Y; Morimoto S; Kimura S; Takano N; Yamashita K; Seki Y; Bokuda K; Yatabe M; Yatabe J; Watanabe D; Ando T; Ichihara A
PLoS One; 2018; 13(4):e0195464. PubMed ID: 29621332
[TBL] [Abstract][Full Text] [Related]
27. [Change in serum G-CSF levels in patients with Graves' disease by treatment with methimazole].
Hara H; Ban Y; Sato R; Ishikawa N; Yoshimura H; Hisaoka T; Ito K
Nihon Naibunpi Gakkai Zasshi; 1992 Oct; 68(10):1121-9. PubMed ID: 1281122
[TBL] [Abstract][Full Text] [Related]
28. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
[TBL] [Abstract][Full Text] [Related]
29. Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels.
Romaldini JH; Werner MC; Rodrigues HF; Teixeira VL; Werner RS; Farah CS; Bromberg N
J Endocrinol Invest; 1986 Jun; 9(3):233-8. PubMed ID: 2428860
[TBL] [Abstract][Full Text] [Related]
30. Ocular Manifestations and Clinical Implications of Serum Immunoglobulin G4 Levels in Graves' Ophthalmopathy Patients.
Luo B; Yuan X; Wang W; Zhang J; Liu R; Hu W; Qi X; Xiang N; Chen L
Ocul Immunol Inflamm; 2022 Apr; 30(3):580-587. PubMed ID: 33054491
[TBL] [Abstract][Full Text] [Related]
31. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease.
Yamada T; Komiya I; Miyahara Y; Komatsu M; Shima I; Inazawa T; Aizawa T
Endocr J; 2006 Dec; 53(6):783-8. PubMed ID: 16983180
[TBL] [Abstract][Full Text] [Related]
32. Erythrocytosis associated with hyperthyroidism: a rare case report and clinical study of possible mechanism.
Liu X; Liu J; Fan L; Shi B
Endocr Res; 2015; 40(4):177-80. PubMed ID: 25775381
[TBL] [Abstract][Full Text] [Related]
33. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M; Girasole G; Pedrazzoni M; Passeri M; Giuliani N; Minelli R; Braverman LE; Roti E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2976-9. PubMed ID: 8768861
[TBL] [Abstract][Full Text] [Related]
34. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy.
Gu X; Zheng L; Chen X; Ruan L; Zhang H; Ge S; Zhu H; Lin X; Shen F
Horm Metab Res; 2012 Jun; 44(6):482-7. PubMed ID: 22473756
[TBL] [Abstract][Full Text] [Related]
36. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease.
Escobar-Morreale HF; Serrano-Gotarredona J; Villar LM; García-Robles R; González-Porqué P; Sancho JM; Varela C
Thyroid; 1996 Feb; 6(1):29-36. PubMed ID: 8777381
[TBL] [Abstract][Full Text] [Related]
37. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
39. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
Leite AC; Pedro AB; Romaldini JH
Horm Metab Res; 2011 Mar; 43(3):194-9. PubMed ID: 21283953
[TBL] [Abstract][Full Text] [Related]
40. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
